Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 713-720

  Morishita, Ryuichi ^a   Makino, Hirofumi ^a   Aoki, Motokuni ^b   Hashiya, Naotaka ^a   Yamasaki, Keita ^a   Azuma, Junya ^a   Taniyama, Yoshiaki ^a   Sawa, Yoshiki ^a   Kaneda, Yasufumi ^a   Ogihara, Toshio ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

gene therapy; growth factors; peripheral arterial disease

Indexed keywords

PLASMID DNA; SCATTER FACTOR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADULT; AGED; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE TRANSFER; HUMAN; LIMB ISCHEMIA; MALE; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ULCER; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WALKING; WOUND HEALING;

AGED; ANKLE BRACHIAL INDEX; CRITICAL ILLNESS; FEMALE; GENE THERAPY; HEMODYNAMICS; HEPATOCYTE GROWTH FACTOR; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; JAPAN; LOWER EXTREMITY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; WALKING; WOUND HEALING;

EID: 79952187006     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219550     Document Type: Article

References (34)

1. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348:370-374. (Pubitemid 26261511)
2. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123. (Pubitemid 28152883)
3. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S, Symes JF. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28:964-973.
4. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998; 98:2800-2804. (Pubitemid 29003959)
5. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, Isner JM. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med. 2000;132:880-884. (Pubitemid 30346850)
6. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933-1938. (Pubitemid 37296537)
7. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP, Hospers GA. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006;17:683-691. (Pubitemid 43970708)
8. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C; Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebocontrolled study: the Euroinject One trial. J Am Coll Cardiol. 2005;45: 982-988. (Pubitemid 40432426)
9. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N; Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42:1339-1347. (Pubitemid 37267270)
10. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as "cytokine supplement therapy." Hypertension. 1999;33:1379-1384. (Pubitemid 29282658)
11. Hayashi S, Morishita R, Nakamura S, Yamamoto K, Moriguchi A, Nagano T, Taizi M, Noguchi H, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: down-regulation of HGF in response to hypoxia in vascular cells. Circulation. 1999;100:II301-II308. (Pubitemid 29523551)
12. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001;8:181-189. (Pubitemid 32186129)
13. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, Nakamura T, Kaneda Y, Higaki J, Ogihara T. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infracted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 2000;7:417-427. (Pubitemid 30156554)
14. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation. 2001;104:2344-2350. (Pubitemid 33049519)
15. Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K, Matsumoto K, Nakamura T, Lawn R, Ogihara T, Kaneda Y. Impairment of collateral formation in Lp(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 2002;105: 1491-1496. (Pubitemid 34263283)
16. Azuma H, Taniyama Y, Takeya Y, Iekushi K, Aoki M, Dosaka N, Matsumoto K, Nakamura T, Ogihara T, Morishita R. Angiogenic and anti-fibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther. 2006;13: 1206-1213. (Pubitemid 44184714)
17. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, Ogihara T. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens. 1996;14:1067-1072. (Pubitemid 26329282)
18. FDA Docket no. 96N-0400: Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Diseases Indications.
19. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, Sawa Y, Matsuda H, Kaneda Y, Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 2004;44:203-209. (Pubitemid 39014240)
20. Yamada A, Matsumoto K, Iwanari H, Sekiguchi K, Kawata S, Matsuzawa Y, Nakamura T. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed Res. 1995;16:105-114.
21. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28:409-413. (Pubitemid 26296043)
22. Becker K, Pan D, Whitley CB. Real-time quantitative polymerase chain reaction to assess gene transfer. Human Gene Ther. 1999;10:2559-2566. (Pubitemid 29489729)
23. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology. 1991;181:277-281.
24. Dormandy J, Mahir M, Ascady G, Balsano F, De-Leeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutshinoff A, Bletry O, Hampton J, Hahler E, Ohlin P, Rieger H, Stranden E, Turpie AGG, Urai L, Verstraete M. Fate of the patient with chronic leg ischaemia: a review article. J Cardiovasc Surg Torino. 1989;30:50-57. (Pubitemid 19080681)
25. Rutherford RB, Flanigan DP, Gupta SK, Johnston KW, Karmondy A, Whittemore AD, Baker D, Ernst CB, Jamieson C, Mehta S. Suggested standards for reports dealing with lower extremity ischemia. Ad Hoc Committee on Reporting Standards Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1986;4:80-94.
26. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M; Circulase Investigators. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006;43:752-759.
27. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67.
28. Powell RJ, Simons M, Mendersohn F, Daniel G, Henry T, Koga M, Morishita R, Annex B. Results of a double-blind placebo-controlled study to assess the safety and efficacy of intramuscular injection of HGF plasmid to improve limb perfusion in patients with critical limb ischemia (HGF-STAT Trial). Circulation. 2008;118:58-65.
29. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360: 427-435.
30. Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, Fukushima M, Matsubara H; TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156:1010-1018.
31. Yoshitomi Y, Kojima S, Umemoto T, Kubo K, Matsumoto Y, Yano M, Sugi T, Kuramochi M. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab. 1999;84: 2425-2458.
32. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, Nakano N, Katsuya T, Nakata S, Takami S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun. 1998;242:238-243. (Pubitemid 28412409)
33. Susen S, Sautiere K, Mouquet F, Cuilleret F, Chmait A, McFadden EP, Hennache B, Richard F, de Groote P, Lablanche JM, Dallongeville J, Bauters C, Jude B, Van Belle E. Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. Eur Heart J. 2005;26:2387-2395. (Pubitemid 41552967)
34. Morishita R, Aoki M, Hashiya N, Yamasaki K, Makino H, Wakayama K, Azuma J, Ogihara T. Hepatocyte growth factor (HGF) angiogenic gene therapy: promises for cardiovascular diseases. Gene Ther Reg. 2002;1: 343-359.